Dalton Einhorn
Nessuna posizione attualmente
Profilo
Prior to joining JJDC, Mr. Einhorn was a Principal with Latterell Venture Partners, a healthcare venture capital firm.
His experience also includes 11 years in the pharmaceutical industry.
At Hoffmann-La Roche, his roles included Product Manager for Demadex and Rocephin.
With Daiichi-Sankyo, Mr. Einhorn held various global pre-launch commercialization leadership roles.
Mr. Einhorn also spent four years in the Mergers & Acquisitions group of Credit Suisse.
Mr. Einhorn received an MBA degree from Yale School of Management and a bachelor’s degree from Drew University.
Precedenti posizioni note di Dalton Einhorn
| Società | Posizione | Fine |
|---|---|---|
ViaCyte, Inc.
 ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Direttore/Membro del Consiglio | - |
| GENOCEA BIOSCIENCES, INC. | Direttore/Membro del Consiglio | - |
Johnson & Johnson Innovation - JJDC, Inc.
 Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | Investitore di Private Equity | - |
| DAIICHI SANKYO CO., LTD. | Corporate Officer/Principal | - |
Novo Nordisk, Inc.
 Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Corporate Officer/Principal | - |
Formazione di Dalton Einhorn
| Yale University | Masters Business Admin |
| Drew University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| DAIICHI SANKYO CO., LTD. | Health Technology |
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
Latterell Venture Partners
 Latterell Venture Partners Investment ManagersFinance Latterell Venture Partners (Latterell Venture Partners) is a venture capital firm founded in 2001 by Pat Latterell. The firm is headquartered in San Ramon, California. | Finance |
Novo Nordisk, Inc.
Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Health Technology |
Johnson & Johnson Innovation - JJDC, Inc.
Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | Finance |
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Health Technology |
- Borsa valori
- Insiders
- Dalton Einhorn
